-
Progres En Urologie : Journal de... Mar 2020
Topics: Humans; Male; Prostatectomy; Prostatic Neoplasms
PubMed: 32682495
DOI: 10.1016/S1166-7087(20)30193-7 -
Cancer Aug 2021
Topics: COVID-19; Cancer Survivors; Delivery of Health Care; Humans; Male; Pandemics; Prostatic Neoplasms
PubMed: 33882148
DOI: 10.1002/cncr.33588 -
European Urology Focus Mar 2020While radiotherapy with androgen deprivation therapy is the current standard of care for the treatment of stage cT4 prostate cancer (PC), surgery may also be an... (Review)
Review
While radiotherapy with androgen deprivation therapy is the current standard of care for the treatment of stage cT4 prostate cancer (PC), surgery may also be an appropriate option in selected patients as part of a multimodal approach. The role and the sequence with which to optimize therapy combinations in this setting are still unknown. This mini review summarizes the current evidence for management of cT4 PC. PATIENT SUMMARY: This mini review examines current evidence for the treatment options for locally advanced prostate cancer. The role of surgery in these patients can be considered as part of a combination treatment strategy along with other modalities such as radiotherapy and hormone therapy.
Topics: Combined Modality Therapy; Humans; Male; Neoplasm Staging; Prostatic Neoplasms
PubMed: 31266732
DOI: 10.1016/j.euf.2019.06.012 -
Asian Journal of Andrology 2019Prostate cancer is among the most common malignancies in Western countries, and its incidence is rapidly rising in Asia where it was traditionally considered an uncommon...
Prostate cancer is among the most common malignancies in Western countries, and its incidence is rapidly rising in Asia where it was traditionally considered an uncommon tumor. Our understanding of the disease and management strategies continue to evolve. The first revolution of its treatment was in the 1940s when hormonal therapy was used to treat patients. The discovery of prostate-specific antigen (PSA) and the subsequent adoption of widespread PSA screening have made it possible to diagnose the disease early, but it was not until recently that the field realized that we had been overdiagnosing and overtreating a large number of men with indolent diseases that will not impact their quality of life or life expectancy. Distinguishing indolent tumors from aggressive ones remains a challenge, although recent advances in multiparametric MRI have given clinicians more confidence in choosing men for active surveillance. However, more need to be done to fundamentally understand the molecular and cellular bases that determine the biologic behavior of each of the tumors.
Topics: Androgen Antagonists; Disease Progression; Humans; Male; Prostatic Neoplasms
PubMed: 30971530
DOI: 10.4103/aja.aja_31_19 -
World Journal of Urology Jan 2022Active surveillance (AS) is an established approach in the management of low-risk, localized prostate cancer. While the use of AS to manage intermediate-risk (IR)... (Review)
Review
INTRODUCTION
Active surveillance (AS) is an established approach in the management of low-risk, localized prostate cancer. While the use of AS to manage intermediate-risk (IR) disease has gradually increased over time, there remains uncertainty with regards to its safety, with only a minority of IR patients currently being managed with this approach.
MATERIALS AND METHODS
We conducted a narrative review based on an analysis of the literature focusing on articles describing AS for IR prostate cancer. We focus on the uncertainty surrounding AS in IR disease by discussing variations in the definitions and guideline recommendations associated with IR disease, and describing the limitations of the evidence from observational studies and randomized trials.
CONCLUSION
The safety of AS for IR disease remains unknown, given the lack of randomized trials and the limitations of the current observational studies. Further research is needed to identify select patients with IR prostate cancer that can be managed safely with AS.
Topics: Humans; Male; Prostatic Neoplasms; Risk Assessment; Watchful Waiting
PubMed: 35044491
DOI: 10.1007/s00345-021-03893-1 -
Advances in Clinical Chemistry 2022Testosterone is an essential steroid hormone associated with a wide variety of biological processes in humans. In prostate cancer, androgen signaling is an important... (Review)
Review
Testosterone is an essential steroid hormone associated with a wide variety of biological processes in humans. In prostate cancer, androgen signaling is an important driver of tumor cell growth. Depletion of gonadal testosterone, achieved by surgical or chemical castration, prevents androgenic signaling and temporally reduces, stops or reverses tumor growth before inevitable progression to castration-resistant prostate cancer occurs. Additional treatment strategies targeting androgenic signaling have become available, although these are without curative intent. While circulating testosterone is also associated with disease risk and potential clinical utility, the main use in the clinical lab is monitoring adequate castration and subsequent resistance to therapy. Adequate castrate testosterone concentrations are currently based on over 50 year-old double-isotope derivative assays that are disputed in automated immunoassay (IA) analysis. The debate has been further fueled with the introduction of mass spectrometry-based assays for testosterone, offering a substantial increase in sensitivity and specificity. In this review, we discuss testosterone regulation and androgen deprivation therapy in prostate cancer. We provide an overview of the developments in testosterone analysis for monitoring adequate castration and resistance to therapy. Current clinical practice and future clinical utility will be discussed. Finally, clinical and research recommendations will be presented.
Topics: Androgen Antagonists; Androgens; Humans; Male; Mass Spectrometry; Middle Aged; Prostatic Neoplasms; Testosterone
PubMed: 35659062
DOI: 10.1016/bs.acc.2021.07.007 -
Journal of Nanobiotechnology Dec 2023Current diagnostic tools for prostate cancer (PCa) diagnosis and risk stratification are insufficient. The hidden onset and poor efficacy of traditional therapies... (Review)
Review
Current diagnostic tools for prostate cancer (PCa) diagnosis and risk stratification are insufficient. The hidden onset and poor efficacy of traditional therapies against metastatic PCa make this disease a heavy burden in global men's health. Prostate cancer-derived extracellular vesicles (PCDEVs) have garnered attention in recent years due to their important role in communications in tumor microenvironment. Recent advancements have demonstrated PCDEVs proteins play an important role in PCa invasion, progression, metastasis, therapeutic resistance, and immune escape. In this review, we briefly discuss the applications of sEV proteins in PCa diagnosis and prognosis in liquid biopsy, focus on the roles of the PCa-derived small EVs (sEVs) proteins in tumor microenvironment associated with cancer progression, and explore the therapeutic potential of sEV proteins applied for future metastatic PCa therapy.
Topics: Male; Humans; Prostatic Neoplasms; Prognosis; Extracellular Vesicles; Liquid Biopsy; Tumor Microenvironment
PubMed: 38093355
DOI: 10.1186/s12951-023-02219-0 -
Nursing Standard (Royal College of... Jun 2016Essential facts Prostate cancer starts in the prostate gland, at the base of the bladder in men. It surrounds the first part of the urethra, which carries urine from the...
Essential facts Prostate cancer starts in the prostate gland, at the base of the bladder in men. It surrounds the first part of the urethra, which carries urine from the bladder. The prostate gland helps in the production of semen, which is also carried in the urethra. It is the most common cancer in men - one in eight will develop it during their lifetime.
Topics: Education, Nursing, Continuing; Humans; Male; Prostate; Prostatic Neoplasms; Risk Factors; United Kingdom
PubMed: 27275890
DOI: 10.7748/ns.30.40.17.s20 -
American Society of Clinical Oncology... May 2023The majority of men with prostate cancer are diagnosed when they are older than 65 years; however, clinical trial participants are disproportionately younger and more... (Review)
Review
The majority of men with prostate cancer are diagnosed when they are older than 65 years; however, clinical trial participants are disproportionately younger and more fit than the real-world population treated in typical clinical practices. It is, therefore, unknown whether the optimal approach to prostate cancer treatment is the same for older men as it is for younger and/or more fit men. Short screening tools can be used to efficiently assess frailty, functional status, life expectancy, and treatment toxicity risk. These risk assessment tools allow for targeted interventions to increase a patient's reserve and improve treatment tolerance, potentially allowing more men to experience the benefit of the significant recent treatment advances in prostate cancer. Treatment plans should also take into consideration each patient's individual goals and values considered within their overall health and social context to reduce barriers to care. In this review, we will discuss evidence-based risk assessment and decision tools for older men with prostate cancer, highlight intervention strategies to improve treatment tolerance, and contextualize these tools within the current treatment landscape for prostate cancer.
Topics: Male; Humans; Aged; Prostatic Neoplasms; Risk Assessment
PubMed: 37207299
DOI: 10.1200/EDBK_390396 -
Clinical Genitourinary Cancer Jun 2023Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published... (Review)
Review
Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published results support the use of taxanes, second-generation antiandrogens or radiotherapy to the primary tumor as part of the treatment in these patients, considering ADT alone as suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for oligometastatic patients in different tumor types. In oligometastatic hormone-sensitive prostate cancer the role of MDT is being studied with promising results. In the present review we assess the available evidence for radiotherapy to the primary tumor in newly diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions in this clinical setting.
Topics: Male; Humans; Prostatic Neoplasms; Androgen Antagonists; Hormones
PubMed: 36456467
DOI: 10.1016/j.clgc.2022.10.015